A quarter of all heart attacks, strokes and operations to open blocked arteries could be avoided in patients with chronic kidney diseases – if the patients take a long term treatment of the blood lipid lowering drugs ezetimibe and simvastatin.
"In this way, about 250,000 people worldwide could be spared from this cardiovascular disease," says principal investigator Professor Colin Baigent of the University of Oxford.
This is the conclusion of the so-called Sharp study, the results of which were presented for the first time at the Nephrology Convention held in the United States on 20 November. This is the largest study of kidney patients ever conducted: It included altogether 9,480 patients from more than 380 hospitals in 18 countries over a time span of ten years. About one third of the patients had already progressed to the stage of dialysis.
Würzburg recruited 1,800 patients
The Department of Medicine I of the University of Würzburg served as a coordinating center for Germany and Austria. Professor Christoph Wanner was the regional coordinator for Central Europe; Associate Professor Vera Krane acted as a study coordinator. "We started the planning in collaboration with Oxford in spring 2001," says Professor Wanner. He and his team recruited altogether 1,800 patients for the study.
The risk of heart attacks and strokes is very high in patients with chronic kidney disease. "Previously, in the prevailing scientific opinion, the higher risk was not thought to be connected to the blood lipid levels so that a reduction of the blood lipid levels would seem to be of no benefit to the patients," says Professor Wanner. This opinion can now be rejected. The fact that blood lipid lowering drugs reduce the risk of cardiovascular diseases in healthy people has long been known.
Side effects of the treatment
"There was no evidence in the study of any adverse side effects of the treatment," says co-principal investigator Martin Landray from Oxford. Earlier concerns that ezetimibe might cause cancer were not confirmed either: "The study clearly shows that the treatment is safe."
Information on chronic kidney disease
Chronic kidney disease is a slowly progressing loss in kidney function over a period of several years. The people most at risk are diabetics, smokers, overweight people and patients with high blood pressure. At the end stage, the kidney function drops to only 15 percent or less. When this stage is reached, renal treatment in form of dialysis or a transplant is required. According to the SHARP study, a reduction of the blood lipid levels is beneficial in any case – no matter how far the disease has already progressed.
Prof. Dr. Christoph Wanner, Department of Medicine I, Nephrology Department, University of Würzburg, T +49 (0)931 201-36330, firstname.lastname@example.org
Robert Emmerich | idw
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences